General information about company |
|||
|---|---|---|---|
| Scrip Code | 524372 | ||
| NSE Symbol | ORCHPHARMA | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE191A01027 | ||
| Name of company | Orchid Pharma Limited | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2025 | ||
| Date of end of financial year | 31-Mar-2026 | ||
| Date of board meeting when results were approved | 12-Aug-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 05-Aug-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | First quarter | ||
| Nature of report standalone or consolidated | Standalone | ||
| Whether results are audited or unaudited for the quarter ended | Unaudited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |||
| Segment Reporting | Single segment | ||
| Description of single segment | Pharmaceutical | ||
| Start date and time of board meeting | 12-Aug-2025 12:00:00 | ||
| End date and time of board meeting | 12-Aug-2025 15:30:00 | ||
| Whether cash flow statement is applicable on company | |||
| Type of cash flow statement | |||
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable | ||
| Whether the company has any related party? | |||
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | |||
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | |||
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | |||
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | |||
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |||
| (b) If answer to above question is No, please explain the reason for not complying. | |||
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | |||
| Latest Date on which RPT policy is updated | |||
| Indicate Company website link for updated RPT policy of the Company | |||
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes | ||
| No. of times funds raised during the quarter | 1 | ||
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No | ||
| Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period. n nAlso, the Company has not raised funds during the quarter but due to the mandatory requirement in technical point of this utility at Row No. 42 of this page is selected as 1. | |||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Standalone | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 1729288000 | ||
| Other income | 159304000 | ||
| Total income | 1888592000 | ||
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 1101574000 | |
| (b) | Purchases of stock-in-trade | 7879000 | |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -120799000 | |
| (d) | Employee benefit expense | 216129000 | |
| (e) | Finance costs | 32575000 | |
| (f) | Depreciation, depletion and amortisation expense | 86541000 | |
| (f) | Other Expenses | ||
| 1 | Other expenses | 382719000 | 382719000 |
| Total other expenses | 382719000 | ||
| Total expenses | 1706618000 | ||
| 3 | Total profit before exceptional items and tax | 181974000 | |
| 4 | Exceptional items | 0 | |
| 5 | Total profit before tax | 181974000 | |
| 6 | Tax expense | ||
| 7 | Current tax | 0 | |
| 8 | Deferred tax | 0 | |
| 9 | Total tax expenses | 0 | |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | |
| 11 | Net Profit Loss for the period from continuing operations | 181974000 | |
| 12 | Profit (loss) from discontinued operations before tax | 0 | |
| 13 | Tax expense of discontinued operations | 0 | |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | |
| 16 | Total profit (loss) for period | 181974000 | |
| 17 | Other comprehensive income net of taxes | -1548000 | |
| 18 | Total Comprehensive Income for the period | 180426000 | |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 507191000 | ||
| Face value of equity share capital | 10 | ||
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 3.59 | ||
| Diluted earnings (loss) per share from continuing operations | 3.59 | ||
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | ||
| Diluted earnings (loss) per share from discontinued operations | 0 | ||
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 3.59 | ||
| Diluted earnings (loss) per share from continuing and discontinued operations | 3.59 | ||
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
Disclosure of notes on financial results |
|||
|---|---|---|---|
| Textual Information(1) | 1. The above results for the quarter and year ended June 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 12, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. n2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. n3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. nAs on June 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : n Statement of QIP Net Funds raised and utilisation nParticulars Amount as stated in Total amount utilised Balance amount as on Remarks n the Offer Document upto June 30, 2025 on June 30, 2025 kept n Rs. In Lakhst Rs. In Lakhs in Fixed Deposits Rs.in lakhs n1. Investment in OBPL, nsubsidiary, for setting up nJammu Manufacturing Facilityt 9000 6461t 2539t n2. Repayment/prepayment, in nfull or in part, of certain noutstanding borrowings navailed by the companyt 14100t 14100t -t n3. Funding capital expenditure n requirements for setting up a n new block at the API facility n of the Company in Alathur, nTamil Nadut 9982 36t 9946 n4. General corporate purposes 6098t 6372t 0t nTotalt 39180 26969t 12485 n nAs per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on June 30, 2025. n Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. n n4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. n5. The figures for the quarters ended 31 March, 2025 represents the balancing figures between audited results for the year ended March 31, 2025 and the published year to date figures up to the third quarter of the relevant year. n6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the nCompany in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, nin compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, ngiving No objection to the said amalgamation. nThe Honourable NCLT vide its order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed with the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. Subsequently, the requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, pursuant to which the Honourable NCLT admitted the petion for its consideration and sanction. n n7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary. | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Apr-2025 | ||||||
| Date of end of reporting period | 30-Jun-2025 | ||||||
| Whether accounts are audited or unaudited | Unaudited | ||||||
| Nature of report standalone or consolidated | Standalone | ||||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Standalone | |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit and loss | -1548000 | -1548000 |
| Total Amount of items that will not be reclassified to profit and loss | -1548000 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0 | |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | |
| 5 | Total Other comprehensive income | -1548000 | |
Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1) |
|
|---|---|
| Mode of Fund Raising | QIP |
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 27-Jun-2023 |
| Amount Raised | 4000000000 |
| Report filed for Quarter ended | 30-Jun-2025 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | Care Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | |
| Comments of the Audit Committee after review | Remark 1nDelay in implementation of the object(s) w.r.t the object- Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu but the extent of delay is not ascertainable. nnCommentnAlathur project is for further processing of proposed 7ACA into intermediate goods or downstream products from Jammu Project. The Land acquisition for setting up 7ACA project at Jammu is delayed. Consequently, there is delay in setting up of API Facility at Alathur. Hence the major amount remained unutilised. Remark 2nDelay in implementation of the object(s) w.r.t the object- Investment in OBPL for setting up Jammu Manufacturing Facility but the extent of delay is not ascertainable.nnCommentnThe Land of around 203.8 Kanal (25.475 acres) at Jammu had been identified, out of which registration of 158.30 Kanal (19.79 acres) of land has completed and registration of the remaining land parcel is expect to be completed before October 2025. Bhoomi Pooja for the project was successfully performed on September 07, 2024. Construction of boundary and building work had been already started. Purchase orders for major equipments have also been placed and delivery of equipments at site will start shortly.nnThe Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) or registration was required. This has led to delay in acquiring land. |
| Comments of the auditors, if any | |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in Jammu | Not Applicable | 900000000 | 0 | 646100000 | 0 | Monitoring Agency in its Report dated August 04, 2025 had comments that The company has transferred Rs 20.45 crores from MA account to CC account as reimbursement of investment already made in OBPL from its own sources. |
| 2 | Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our Company | Not Applicable | 1410000000 | 0 | 1410000000 | 0 | |
| 3 | Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu | Not Applicable | 998200000 | 0 | 3600000 | 0 | |
| 4 | General Corporate Purposes | Not Applicable | 609800000 | 0 | 637200000 | 0 | As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs. |
Signatory Details |
|
|---|---|
| Name of signatory | Kapil Dayya |
| Designation of person | Company Secretary and Compliance Officer |
| Place | Gurugram |
| Date | 12-Aug-2025 |